A balanced analysis of the trade-offs between building an in-house medical writing function and partnering with a specialist provider — covering cost, quality control, flexibility, and regulatory risk. Includes a framework for evaluating which model suits different stages of a biotech company’s growth. Targeted at VP-level regulatory and clinical development leaders at emerging biotech organisations.

Data integrity remains one of the most cited issues in FDA Warning Letters and EMA GMP deficiency reports. This article explains the ALCOA+ principles in plain language, identifies the highest-risk data systems in pharmaceutical operations, and outlines a practical remediation framework. Targeted at quality assurance professionals and laboratory managers.

A clear breakdown of the shift from traditional Computer System Validation (CSV) to the FDA’s newer Computer Software Assurance (CSA) framework — what changed, what stayed the same, and how to practically adapt your validation programmes. Ideal for IT compliance managers and quality professionals responsible for GxP system validation.

An in-depth look at the most common observations from recent FDA 483s and EMA GMP deficiency reports — with practical guidance on how companies can proactively address gaps before inspectors arrive. Covers data integrity, CAPA quality, training records, and SOP management. Written for quality directors and site heads at pharmaceutical manufacturing facilities.

A practical guide exploring how the quality of regulatory documentation directly affects submission review timelines and approval outcomes. Covers common errors in CSRs and CTD narratives, the cost of poor documentation, and what review-ready documents actually look like. Ideal for regulatory affairs managers and CMC teams at mid-size pharma companies preparing for NDA or MAA […]